Transfusion Therapy in Reoperative Cardiac Surgery

  • Anand Padmanabhan
  • Darrell J. TriulziEmail author


Cardiac surgery can be complicated by significant bleeding, particularly in patients with prior cardiothoracic surgery. Redo cardiac procedures can be complicated by adhesions and prolonged cardiopulmonary bypass (CPB), both of which can contribute to excessive bleeding. Approximately 30% of patients undergoing first-time elective coronary artery bypass grafting (CABG) surgery require a blood transfusion (Transfusion 41: 1193–203, 2001), and the likelihood of transfusion is even higher in cardiac reoperations (odds ratio 2.32; confidence interval 1.53–2.33) (Transfusion 46: 1120–9, 2006). Thus, the cardiothoracic surgeon and anesthesiologist need to be aware of the symptoms, signs, relevant laboratory tests, pathophysiology, and management strategies for excessive bleeding in the perioperative period of redo cardiac surgery.


Coronary Artery Bypass Grafting International Normalize Ratio Factor VIIa Disseminate Intravascular Coagulation Tranexamic Acid 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Karkouti K, Cohen MM, McCluskey SA, Sher GD. A multivariable model for predicting the need for blood transfusion in patients undergoing first-time elective coronary bypass graft surgery. Transfusion. 2001;41:1193–203.PubMedCrossRefGoogle Scholar
  2. 2.
    Alghamdi AA, Davis A, Brister S, et al. Development and validation of transfusion risk understanding scoring tool (TRUST) to stratify cardiac surgery patients according to their blood transfusion needs. Transfusion. 2006;46:1120–9.PubMedCrossRefGoogle Scholar
  3. 3.
    Ferraris VA, Ferraris SP, Saha SP, et al. Perioperative blood transfusion and blood conservation in cardiac surgery: the society of thoracic surgeons and the society of cardiovascular anesthesiologists clinical practice guideline. Ann Thorac Surg. 2007;83:S27–86.PubMedCrossRefGoogle Scholar
  4. 4.
    Yavari M, Becker RC. Coagulation and fibrinolytic protein kinetics in cardiopulmonary bypass. J Thromb Thrombolysis. 2009;27:95–104.PubMedCrossRefGoogle Scholar
  5. 5.
    Despotis GJ, Joist JH, Hogue Jr CW, et al. The impact of heparin concentration and activated clotting time monitoring on blood conservation. A prospective, ­randomized evaluation in patients undergoing cardiac operation. J Thorac Cardiovasc Surg. 1995;110:46–54.PubMedCrossRefGoogle Scholar
  6. 6.
    Mochizuki T, Olson PJ, Szlam F, et al. Protamine reversal of heparin affects platelet aggregation and activated clotting time after cardiopulmonary bypass. Anesth Analg. 1998;87:781–5.PubMedGoogle Scholar
  7. 7.
    Shore-Lesserson L, Manspeizer HE, DePerio M, et al. Thromboelastography-guided transfusion algorithm reduces transfusions in complex cardiac surgery. Anesth Analg. 1999;88:312–9.PubMedGoogle Scholar
  8. 8.
    Royston D, von Kier S. Reduced haemostatic factor transfusion using heparinase-modified thrombelastography during cardiopulmonary bypass. Br J Anaesth. 2001;86:575–8.PubMedCrossRefGoogle Scholar
  9. 9.
    Samama CM, Ozier Y. Near-patient testing of haemostasis in the operating theatre: an approach to appropriate use of blood in surgery. Vox Sang. 2003;84:251–5.PubMedCrossRefGoogle Scholar
  10. 10.
    Murphy MF, Wallington TB, Kelsey P, et al. Guidelines for the clinical use of red cell transfusions. Br J Haematol. 2001;113:24–31.PubMedCrossRefGoogle Scholar
  11. 11.
    Wang G, Bainbridge D, Martin J, Cheng D. The efficacy of an intraoperative cell saver during cardiac surgery: a meta-analysis of randomized trials. Anesth Analg. 2009;109:320–30.PubMedCrossRefGoogle Scholar
  12. 12.
    Bracey AW, Radovancevic R, Riggs SA, et al. Lowering the hemoglobin threshold for transfusion in coronary artery bypass procedures: effect on patient outcome. Transfusion. 1999;39:1070–7.PubMedCrossRefGoogle Scholar
  13. 13.
    Spotnitz WD, Burks S. Hemostats, sealants, and adhesives: components of the surgical toolbox. Transfusion. 2008;48:1502–16.PubMedCrossRefGoogle Scholar
  14. 14.
    Fung MK, Moore K, Ridenour M, et al. Clinical effects of reverting from leukoreduced to nonleukoreduced blood in cardiac surgery. Transfusion. 2006;46:386–91.PubMedCrossRefGoogle Scholar
  15. 15.
    Vamvakas EC. WBC-containing allogeneic blood transfusion and mortality: a meta-analysis of randomized controlled trials. Transfusion. 2003;43:963–73.PubMedCrossRefGoogle Scholar
  16. 16.
    Boshkov LK, Furnary A, Morris C, et al. Prestorage leukoreduction of red cells in elective cardiac surgery: results of a double blind randomized controlled trial. Blood. 2004;104:112a.Google Scholar
  17. 17.
    Boshkov LK, Chien G, VanWinkle G, et al. Prestorage leukoreduction of transfused red cells is associated with significant ongoing 2–12 month survival benefit in cardiac surgery patients. Blood. 2004;104:174a.Google Scholar
  18. 18.
    Zimrin AB, Hess JR. Current issues relating to the transfusion of stored red blood cells. Vox Sanguinis. 2009;96:93–103.PubMedCrossRefGoogle Scholar
  19. 19.
    Lelubre C, Piagnerelli M, Vincent JL. Association between duration of storage of transfused red blood cells and morbidity and mortality in adult patients: myth or reality? Transfusion. 2009;49:1384–94.PubMedCrossRefGoogle Scholar
  20. 20.
    Hall K, Forrest P, Sawyer C. The effects of acidosis and hypothermia on blood transfusion requirements following factor VII administration. Anaesth Intensive Care. 2007;35:494–7.PubMedGoogle Scholar
  21. 21.
    Fergusson DA, Hebert PC, Mazer CD, et al. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med. 2008;358:2319–31.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.Department of Pathology, Division of Transfusion MedicineUniversity of Pittsburgh School of MedicinePittsburghUSA

Personalised recommendations